Skip NavigationSkip to Content
Return Return to Search Results

A Therapeutic Dendritic Cell-Based Vaccine for HIV-1 Infection

  1. Author:
    Garcia, F.
    Climent, N.
    Assoumou, L.
    Gil, C.
    Gonzalez, N.
    Alcami, J.
    Leon, A.
    Romeu, J.
    Dalmau, J.
    Martinez-Picado, J.
    Lifson, J.
    Autran, B.
    Costagliola, D.
    Clotet, B.
    Gatell, J. M.
    Plana, M.
    Gallart, T.
    Obje, D. M. A. V. R.

  2. Author Address

    [Garcia, Felipe; Climent, Nuria; Gil, Cristina; Leon, Agathe; Gatell, Josep M.; Gallart, Teresa] Univ Barcelona, Hosp Clin Barcelona, HIV Dev Program Catalonia, Infect Dis Dept,Inst Invest Biomed August Pi & Su, E-08036 Barcelona, Spain. [Martinez-Picado, Javier] Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain. [Gonzalez, Nuria; Alcami, Jose] Inst Salud Carlos III, AIDS Immunopathogenesis Unit, Ctr Nacl Microbiol, Madrid, Spain. [Romeu, Joan; Clotet, Bonaventura] Hosp Badalona Germans Trias & Pujol, Lluita SIDA Fdn, Badalona, Spain. [Dalmau, Judith; Martinez-Picado, Javier; Clotet, Bonaventura] IrsiCaixa Fdn, HIV Dev Program Catalonia, Badalona, Spain. [Assoumou, Lambert; Costagliola, Dominique] INSERM, U943, Paris, France. [Assoumou, Lambert; Costagliola, Dominique] Univ Paris 06, Unite Mixte Rech Sante 943, Hop La Pitie Salpetriere, Paris, France. [Autran, Brigitte] Univ Paris 06, Unite Mixte Rech Sante 945, Hop La Pitie Salpetriere, INSERM, Paris, France. [Lifson, Jeff] Sci Applicat Int Corp, AIDS & Canc Virus Program, Frederick, MD USA. [Plana, Montserrat] NCI, Frederick, MD 21701 USA.;Garcia, F, Univ Barcelona, Hosp Clin Barcelona, HIV Dev Program Catalonia, Infect Dis Dept,Inst Invest Biomed August Pi & Su, Villarroel 170, E-08036 Barcelona, Spain.;fgarcia@clinic.ub.es
    1. Year: 2011
    2. Date: Feb
  2. Journal: Journal of Infectious Diseases
    1. 203
    2. 4
    3. Pages: 473-478
  4. Type of Article: Article
  5. ISSN: 0022-1899
  1. Abstract:

    A double-blinded, controlled study of vaccination of untreated patients with chronic human immunodeficiency virus type 1 (HIV-1) infection with 3 doses of autologous monocyte-derived dendritic cells (MD-DCs) pulsed with heat inactivated autologous HIV-1 was performed. Therapeutic vaccinations were feasible, safe, and well tolerated. At week 24 after first vaccination (primary end point), a modest significant decrease in plasma viral load was observed in vaccine recipients, compared with control subjects (P = .03). In addition, the change in plasma viral load after vaccination tended to be inversely associated with the increase in HIV-specific T cell responses in vaccinated patients but tended to be directly correlated with HIV-specific T cell responses in control subjects.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1093/infdis/jiq077
  3. View record in Web of Science®
  4. WOS: 000286468700006

Library Notes

  1. Fiscal Year: FY2010-2011
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel